Related Experiment Video

Updated: Feb 23, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K

Prevalence of G6PD deficiency in Children with Hepatitis A

Ghasem Miri-Aliabad1, Ali Khajeh2, Tooran Shahraki2

  • 1Assistant Professor of Pediatric Hematology-Oncology, Children and Adolescent Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

International Journal of Hematology-Oncology and Stem Cell Research
|September 7, 2017
PubMed

Insights

Hepatitis A is common, and this study found a high prevalence of glucose 6-phosphate dehydrogenase (G6PD) deficiency in children with this infection. Testing for G6PD deficiency is recommended in endemic areas.

Area of Science:

  • Pediatrics
  • Hepatology
  • Hematology

Background:

  • Hepatitis A virus (HAV) is a leading cause of viral hepatitis globally.
  • Clinical presentations of HAV infection vary widely.
  • Glucose 6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzyme disorder.

Purpose of the Study:

  • To investigate clinical findings in children diagnosed with Hepatitis A.
  • To determine the prevalence of G6PD deficiency among pediatric Hepatitis A patients.

Main Methods:

  • Prospective study design.
  • Inclusion of 117 children with Hepatitis A confirmed by anti-HAV IgM antibody.
  • Measurement of G6PD enzyme activity using the fluorescent spot test.

Main Results:

  • The majority of patients (55.6%) were female, with a mean age of 2.79 years.
  • Common symptoms included dark yellow urine and anorexia.
  • G6PD deficiency was identified in 26.3% of tested pediatric patients.

Conclusions:

  • High prevalence of G6PD deficiency in pediatric Hepatitis A cases suggests a need for routine screening.
  • Recommendations include measuring G6PD levels alongside liver function tests in endemic regions.
  • Close monitoring for hemolysis and renal function is advised for these patients.

Keywords:
ChildrenG6PD deficiencyHepatitis A

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K
Hepatic Progenitor Specification from Pluripotent Stem Cells using a Defined Differentiation System07:09

Hepatic Progenitor Specification from Pluripotent Stem Cells using a Defined Differentiation System

Published on: May 10, 2020

5.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
946
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
303
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
301